LON:EVG Evgen Pharma (EVG) Share Price, News & Analysis → Must-See: Elon’s New Invention is Absolutely Insane (From InvestorPlace) (Ad) Free EVG Stock Alerts GBX 0.80 0.00 (0.00%) (As of 04/25/2024) Add Compare Share Share Today's Range 0.80▼ 0.8050-Day Range 0.75▼ 0.9152-Week Range 0.70▼ 4.05Volume227,410 shsAverage Volume1.73 million shsMarket Capitalization£3.42 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartHeadlinesStock AnalysisChartHeadlines Get Evgen Pharma alerts: Email Address Ad Wealthpin ProTrump’s Gift Could Unleash $51 Billion in New WealthIn January 2021, Donald Trump silently rolled out a special gift to the American public… One that top house republicans called “The Key To America’s Economic Future”.You just have to make this simple move before July 30, 2024. About Evgen Pharma Stock (LON:EVG)Evgen Pharma plc, a clinical stage drug development company, focuses on the development of sulforaphane-based medicines for the treatment of cancer and inflammatory diseases. It develops its products using Sulforadex, a sulforaphane stabilization technology. The company's lead product is SFX-01, that is in Phase II clinical trials for the treatment of metastatic breast cancer; and in Phase Ib/IIa clinical trials for the treatment of glioblastoma, as well as in preclinical stage for the treatment of haematological malignancies and analogues. It also provides out-licensing of its technology services. Evgen Pharma plc was incorporated in 2014 and is headquartered in Nether Alderley, the United Kingdom.Read More EVG Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EVG Stock News HeadlinesApril 4, 2024 | lse.co.ukTRADING UPDATES: Northcoders launches bootcamp; Schroder investsMarch 20, 2024 | marketwatch.comEvgen to Raise Up to $2.4 Mln; to Change Name After Acquiring Chronos TherapeuticsFebruary 27, 2024 | lse.co.ukEvgen Pharma finds evidence of SFX-01 activity in colon cancer modelsFebruary 14, 2024 | msn.comPharma middlemen face govt. scrutiny over generic drug shortagesJanuary 26, 2024 | lse.co.ukEvgen Pharma Share ChatDecember 4, 2023 | finance.yahoo.comMetastatic HR+/HER2− Breast Cancer Market is Expected to Showcase a Significant Growth at a CAGR of 9.3% by 2032, Predicts DelveInsightOctober 31, 2023 | finance.yahoo.comEvgen Pharma "delighted" with cash position after promising first halfSeptember 5, 2023 | lse.co.ukEvgen Pharma hires interim CFO from Faron, chair to retire this monthSeptember 5, 2023 | marketwatch.comEvgen Pharma Chair Barry Clare Steps Down; Appoints New Interim Chair, Interim CFOAugust 15, 2023 | marketwatch.comEvgen Pharma Shares Rise on Positive SFX-01 Tablet ReportAugust 2, 2023 | marketwatch.comEvgen Pharma Shares Fall on Ending of License DealJune 19, 2023 | lse.co.ukEvgen collaborator receives grant from KWF Dutch Cancer SocietyJune 7, 2023 | lse.co.ukEvgen Pharma confident amid Stalicla deal; CFO Moulson to retireMarch 22, 2023 | marketwatch.comEvgen Pharma Results From SFX-01 Tablet Trial Meet ExpectationsMarch 16, 2023 | marketwatch.comEvgen Pharma Shares Rise on Drug Candidate DataMarch 13, 2023 | msn.comTHG and musicMagpie move to reassure investors as Silicon Valley Bank's UK arm is sold to HSBCNovember 16, 2022 | lse.co.ukEvgen Pharma starts clinical trial of new SFX-01 tabletOctober 13, 2022 | lse.co.ukCORRECT: Coral Products buys Ecodeck; Evgen Pharma recruitsOctober 12, 2022 | lse.co.ukTRADING UPDATES: Coral Products buys Ecodeck; Evgen Pharma recruitsOctober 11, 2022 | lse.co.ukAIM WINNERS & LOSERS: Europa Oil, i3 Energy slide as well disappointsOctober 11, 2022 | finance.yahoo.comCompanies Like Evgen Pharma (LON:EVG) Are In A Position To Invest In GrowthOctober 10, 2022 | proactiveinvestors.com.auMarket movers: Electricity generators fall on revenue cap reportsOctober 10, 2022 | msn.comShares in drug maker more then double after agreeing $160m dealOctober 10, 2022 | benzinga.comSTALICLA to in-license SFX-01 from Evgen for neurodevelopment disorder indicationsOctober 10, 2022 | marketwatch.comEvgen Pharma Shares Jump After Securing Licensing Deal for Up to $160.5 MlnSee More Headlines Receive EVG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Evgen Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings6/15/2020Today6/03/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:EVG CUSIPN/A CIKN/A Webevgen.com Phone+44-151-7053532FaxN/AEmployees10Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (0.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-3,350,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-60.57% Return on Assets-45.52% Debt Debt-to-Equity RatioN/A Current Ratio10.39 Quick Ratio23.15 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowGBX 0.47 per share Price / Cash Flow1.71 Book ValueGBX 1 per share Price / Book0.80Miscellaneous Outstanding Shares427,350,000Free FloatN/AMarket Cap£3.42 million OptionableNot Optionable Beta1.44 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesDr. Huw Jones BSc (Age 65)Ph.D., CEO & Executive Director Comp: $304.73kMr. Toni Haenninen (Age 47)CFO & Director Dr. Helen KuhlmanChief Business OfficerDr. Glen Clack FFPMM.D., Chief Medical OfficerKey CompetitorsRealm TherapeuticsLON:RLMSynairgenLON:SNGGenflow BiosciencesLON:GENFImmuPharmaLON:IMMBiVictriX TherapeuticsLON:BVXView All CompetitorsInsidersToni HänninenBought 1,000,000 shares on 4/5/2024Total: £1 M ($1.00/share) EVG Stock Analysis - Frequently Asked Questions How have EVG shares performed in 2024? Evgen Pharma's stock was trading at GBX 1.60 at the beginning of the year. Since then, EVG shares have decreased by 50.0% and is now trading at GBX 0.80. View the best growth stocks for 2024 here. How were Evgen Pharma's earnings last quarter? Evgen Pharma plc (LON:EVG) released its quarterly earnings data on Monday, June, 15th. The company reported ($2.10) EPS for the quarter, meeting analysts' consensus estimates of ($2.10). What other stocks do shareholders of Evgen Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Evgen Pharma investors own include MOTIF BIO PLC/S (MTFB), Capital & Counties Properties PLC (CAPC), Obtala (OBT), Tertiary Minerals (TYM), Veltyco Group (VLTY), Atalaya Mining (AYM), AllianceBernstein Global High Income Fund (AWF), Advent Convertible and Income Fund (AVK), Ares Dynamic Credit Allocation Fund (ARDC) and UBS ETRACS Alerian MLP Index ETN (AMU). How do I buy shares of Evgen Pharma? Shares of EVG stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:EVG) was last updated on 6/3/2024 by MarketBeat.com Staff From Our PartnersNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemWeiss RatingsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaAre You Positioned For The New Energy Goldrush?Wealthpin ProNext President (Not Trump. Not Biden.)The Freeport SocietyCollapse of the Petrodollar Colonial Metals[Webinar] Understanding Covered CallsOICWhat’s Pelosi Buying Now?AltimetryAlex's "Next Magnificent Seven" StocksThe Oxford Club Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evgen Pharma plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.